Soleno Therapeutics, Inc.

NASDAQ:SLNO

53.55 (USD) • At close September 18, 2024
Bedrijfsnaam Soleno Therapeutics, Inc.
Symbool SLNO
Munteenheid USD
Prijs 53.55
Beurswaarde 2,081,574,180
Dividendpercentage 0%
52-weken bereik 3.96 - 54.5
Industrie Biotechnology
Sector Healthcare
CEO Dr. Anish Bhatnagar M.D.
Website https://soleno.life

An error occurred while fetching data.

Over Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development

Vergelijkbare Aandelen

Cosmos Health Inc. logo

Cosmos Health Inc.

COSM

1.11 USD

Acutus Medical, Inc. logo

Acutus Medical, Inc.

AFIB

0.083 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)